Market Overview:
The global non-small cell lung cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of lung cancer, technological advancements in the field of oncology, and rising demand for targeted therapies. Based on type, the global non-small cell lung cancer drugs market can be segmented into biologics, small molecule targeted therapy, chemotherapy, and other therapies. The biologics segment is expected to account for the largest share of the market in 2018 owing to its high efficacy and growing demand among patients. Based on application, the market can be divided into lung adenocarcinoma, squamous cell lung carcinoma (SCLC), and large-cell lung carcinoma (LCLC). The LCLC segment is projected to grow at a highest CAGR during the forecast period owing to increasing incidence rates of this type of cancer across regions.
Product Definition:
Non-small cell lung cancer drugs are used to treat non-small cell lung cancer, a type of lung cancer. These drugs work by slowing or stopping the growth of the tumor.
Biologics:
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer. According to the American Cancer Society, in 2019, there were an estimated 163,200 new cases and around 96,000 deaths due to NSCLC in the U.S. Biologics plays a major role in treating this type of cancer owing to its ability to target and destroy abnormal cells without harming healthy tissues.
Small Molecule Targeted Therapy:
Small molecule targeted therapy is a type of chemotherapy which works by targeting and destroying cancer cells with the help of special molecules known as drugs. These molecules are designed to interact with specific proteins or DNA sequences present in the cancer cells, which then leads to cell death.
Application Insights:
The lung adenocarcinoma segment dominated the global non-small cell lung cancer drugs market in 2017. This is attributed to the availability of a number of products for this type of cancer, including cetuximab, bevacizumab, and panitumumab.
Cetuximab is an antibody drug that targets epidermal growth factor receptor (EGFR) and ErbB2. It has been approved by U.S FDA for the treatment of patients with metastatic non-small cell lung cancer as well as EGFR positive breast carcinoma.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high R&D investment by companies, and availability of effective healthcare infrastructure. Moreover, favorable reimbursement policies for oncological treatment are also expected to boost revenue growth in this region during the forecast period. Asia Pacific is estimated to witness lucrative CAGR over the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as China & India. Furthermore, government initiatives encouraging generic competition are also expected favorably impact revenue growth during the same period (2018-2030).
In 2016; China accounted for approximately 20% share in terms of revenue generation among all Asian countries due mainly expansionary monetary polices implemented by Chinese central bank which resulted into increased domestic consumption along with growing exports from major manufacturers such as Shanghai Pharmaceutical Co.
Growth Factors:
- Increasing incidence of lung cancer
- Growing demand for targeted therapies
- Rising prevalence of smoking and air pollution
- Technological advancements in diagnosis and treatment of lung cancer
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-small Cell Lung Cancer Drugs Market Research Report
By Type
Biologics, Small Molecule Targeted Therapy, Chemotherapy, Other
By Application
Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Large-cell Lung Carcinoma
By Companies
AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Non-small Cell Lung Cancer Drugs Market Report Segments:
The global Non-small Cell Lung Cancer Drugs market is segmented on the basis of:
Types
Biologics, Small Molecule Targeted Therapy, Chemotherapy, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Large-cell Lung Carcinoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
Highlights of The Non-small Cell Lung Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biologics
- Small Molecule Targeted Therapy
- Chemotherapy
- Other
- By Application:
- Lung Adenocarcinoma
- Squamous Cell Lung Carcinoma
- Large-cell Lung Carcinoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-small Cell Lung Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-small cell lung cancer drugs are medications that are used to treat the disease. These drugs can help to shrink tumors and improve the quality of life for patients.
Some of the key players operating in the non-small cell lung cancer drugs market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc..
The non-small cell lung cancer drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-small Cell Lung Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-small Cell Lung Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-small Cell Lung Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-small Cell Lung Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-small Cell Lung Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Non-small Cell Lung Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Non-small Cell Lung Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Non-small Cell Lung Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
5.2.1 Biologics
5.2.2 Small Molecule Targeted Therapy
5.2.3 Chemotherapy
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Non-small Cell Lung Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
6.2.1 Lung Adenocarcinoma
6.2.2 Squamous Cell Lung Carcinoma
6.2.3 Large-cell Lung Carcinoma
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-small Cell Lung Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-small Cell Lung Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Non-small Cell Lung Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
9.6.1 Biologics
9.6.2 Small Molecule Targeted Therapy
9.6.3 Chemotherapy
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
9.10.1 Lung Adenocarcinoma
9.10.2 Squamous Cell Lung Carcinoma
9.10.3 Large-cell Lung Carcinoma
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Non-small Cell Lung Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
10.6.1 Biologics
10.6.2 Small Molecule Targeted Therapy
10.6.3 Chemotherapy
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
10.10.1 Lung Adenocarcinoma
10.10.2 Squamous Cell Lung Carcinoma
10.10.3 Large-cell Lung Carcinoma
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Non-small Cell Lung Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
11.6.1 Biologics
11.6.2 Small Molecule Targeted Therapy
11.6.3 Chemotherapy
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
11.10.1 Lung Adenocarcinoma
11.10.2 Squamous Cell Lung Carcinoma
11.10.3 Large-cell Lung Carcinoma
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Non-small Cell Lung Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
12.6.1 Biologics
12.6.2 Small Molecule Targeted Therapy
12.6.3 Chemotherapy
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
12.10.1 Lung Adenocarcinoma
12.10.2 Squamous Cell Lung Carcinoma
12.10.3 Large-cell Lung Carcinoma
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Non-small Cell Lung Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Non-small Cell Lung Cancer Drugs Market Size Forecast by Type
13.6.1 Biologics
13.6.2 Small Molecule Targeted Therapy
13.6.3 Chemotherapy
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Non-small Cell Lung Cancer Drugs Market Size Forecast by Applications
13.10.1 Lung Adenocarcinoma
13.10.2 Squamous Cell Lung Carcinoma
13.10.3 Large-cell Lung Carcinoma
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-small Cell Lung Cancer Drugs Market: Competitive Dashboard
14.2 Global Non-small Cell Lung Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Bristol-Myers Squibb Company
14.3.3 Eli Lilly and Company
14.3.4 F. Hoffmann-La Roche Ltd
14.3.5 Merck & Co., Inc.
